Alan Rawle Accepted as a Fellow of The Royal Society of Chemistry
Alan Rawle, Divisional Applications Manager at Malvern Instruments (Malvern, UK), has been accepted as a Fellow of the Royal Society of Chemistry (FRSC).
Alan Rawle, Divisional Applications Manager at Malvern Instruments (Malvern, UK), has been accepted as a Fellow of the Royal Society of Chemistry (FRSC).
The RSC fellowship was awarded to Rawle for his extensive work with laser diffraction and other particle characterization techniques for more than two decades. It recognizes his service and continued contributions to analytical chemistry.
David Higgs, Head of Marketing at Malvern, said: “ We are delighted that the Royal Society of Chemistry has chosen to honour Alan Rawle and offer many congratulations”. He added that Rawle has had a significant impact on both the company and the scientific community as a whole.
For more information please visit:
www.malvern.com
Mitigating High Sample Volume Consumption in AAV Aggregate Analysis Using a Biozen™ dSEC-7 by SEC-FL
April 15th 2024This application note showcases a Biozen dSEC-7 SEC chemistry/fluorescence detector solution, offering reliable AAV aggregate analysis in under 10 minutes with as little as 0.5 µL of sample. Across four AAV serotypes, resolution between monomer and aggregates remains consistently high, emphasizing Biozen dSEC-7's efficiency and ability to maintain accurate detection at minimal injection volumes. Ideal for routine testing, this solution ensures precise measurement of a CQA with streamlined sample consumption.
Adeno-Associated Virus (AAV) Serotype Screen Using a Biozen™ dSEC-7 Size Exclusion Column
April 15th 2024With its 700 Å large pore silica particle and hydrophilic diol-type surface chemistry, Biozen dSEC-7 provides excellent resolution of monomer from dimer peaks in under 8 minutes across four different AAV serotypes. This capability is crucial for optimizing gene therapy biopharmaceuticals, ensuring thorough analytical scrutiny to select the most appropriate serotype(s) for enhanced therapeutic outcomes and immunogenic profiles.
